WHO Pharmaceuticals Newsletter 2004, No. 06
(2004; 13 pages) View the PDF document
Table of Contents
Close this folderREGULATORY MATTERS
View the documentACTRA-RX AND YILISHEN - Presence of undeclared sildenafil
View the documentADALIMUMAB - Serious infections if used together with anakinra
View the documentANTIDEPRESSANTS Label to warn of increased suicidality in children; Patient Medication Guide to advise on risks and precautions to be taken
View the documentATORVASTATIN - Interaction with grapefruit juice
View the documentBLACK COHOSH COMBINATION #2; YELLOW DOCK COMBINATION #3 - Presence of aristolochic acid
View the documentCELECOXIB - Withdrawn in Turkey
View the documentEPOETIN ALFA - Label change to reflect thrombosis risk
View the documentETANERCEPT, INFLIXIMAB - Reports of serious infections
View the documentINFLIXIMAB - Lymphoma warning added to US Remicade label
View the documentISOTRETINOIN - Enhancement to risk management programme
View the documentLEVOTHYROXINE SODIUM - Dysphagia and risk of choking
View the documentMIFEPRISTONE - Important labelling changes proposed
View the documentPERGOLIDE MESYLATE - Label change: risk of cardiac valvulopathy
View the documentREMINYL AND AMARYL - Reports of medication errors
View the documentVALDECOXIB - Label updated to warn about skin reactions
Open this folder and view contentsSAFETY OF MEDICINES
View the documentFEATURE
 

ATORVASTATIN - Interaction with grapefruit juice

UK. The Summary of Product Characteristics (SPC) for atorvastatin (Lipitor) has been revised to include the interaction between atorvastatin and grapefruit juice. The SPC now states that grapefruit juice contains one or more components that inhibit CYP3A4 and can increase plasma concentrations of drugs metabolised by CYP3A4. Concomitant intake of large quantities of grapefruit juice and atorvastatin is therefore not recommended.

Reference:

SPC for Lipitor, http://emc.medicines.org.uk, 10 November 2004.

to previous section to next section
 

Last updated: May 3, 2013